Sort   by:  
 Page size 

Non-small cell lung cancer is a malignant tumor with high morbidity and mortality worldwide. Eleutherococcus senticosus can induce apoptosis in non-small cell lung cancer cells, but the mechanism remains unclear. This study aimed to elucidate the role of Eleutherococcus senticosus in inducing apo...

2025-05-12 | MTBLS10545 | MetaboLights
We collected baseline fecal samples from 85 patients with newly diagnosed lung cancer, 51 patients with bone metastasis (M group), and 34 patients without bone metastasis (N group). We conducted metagenomic and metabolomic sequencing to compare the differences in gut microbiota and metabolites betwe...
2026-07-10 | MTBLS15004 | MetaboLights

Gut microbiota has been reported to be associated with the host’s immune system and immunotherapy response, as well as immune-related adverse events (irAEs). Additionally, gut microbial metabolites have various immunomodulatory effects. Our study focused on the differences in gut microbiota and t...

2025-12-23 | MTBLS13557 | MetaboLights
Chemotherapy combined with checkpoint blockade antibodies targeting programmed cell death protein (PD-1) has achieved remarkable success in non-small cell lung cancer (NSCLC). However, few patients benefit from long-term treatment. Therefore, biomarkers capable of guiding the optimal therapeutic sel...
2025-06-16 | MTBLS11232 | MetaboLights

After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanism will be explored through in vivo and i...

2026-09-03 | MTBLS13812 | MetaboLights

After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanism will be explored through in vivo and i...

2026-09-03 | MTBLS13811 | MetaboLights

After screening the bacteria both in vivo and in vitro, it was found that a certain candidate strain could significantly inhibit non-small cell lung cancer when combined with the drug gefitinib and alleviate the side effects of gefitinib. Next, the mechanis...

2026-09-03 | MTBLS13843 | MetaboLights
Not available
ORGANISM(S): Homo sapiens 
Lung cancer remains the most common cause of cancer deaths worldwide, yet there is currently a lack of diagnostic noninvasive biomarkers that could guide treatment decisions. Small molecules (<1500 Da) were measured in urine collected from 469 lung cancer patients and 536 population controls using u...
2014-05-06 | MTBLS28 | MetaboLights

The effectiveness of immunotherapy varies among patients with advanced non-small cell lung cancer (NSCLC). Here we investigated the baseline immune status in stage IV NSCLC patients treated with anti-PD-1 plus chemotherapy to understand the immune mechanisms and unveil systemic markers associated...

2025-10-16 | MTBLS13150 | MetaboLights
Sort   by:  
 Page size